Advertisement

Diabetologia

, Volume 39, Issue 2, pp 149–160 | Cite as

Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells

  • A. Gugliucci
  • M. Bendayan
Originals

Summary

The presence of excessive amounts of advanced glycation end products (AGE) in tissues or in the circulation may critically affect the progression of diabetic nephropathy. Circulating AGE levels, mainly in the form of small peptides, increase in diabetic patients or in patients with end-stage renal disease. This rise correlates with the severity of the nephropathy. However, so far little is known about the fate of AGE-proteins and AGE-peptides in renal tissue, and in order to elucidate this issue we undertook the present study. AGE-bovine serum albumin (AGE-BSA) and AGE-peptides were prepared, characterized by spectrophotometry, spectrofluorometry, chromatography and SDS-PAGE. AGE-peptides reacted in vitro with LDL producing biochemical and ultrastructural modifications. Using colloidal gold post-embedding immunoelectron microscopy with an anti-AGE antibody generated in our laboratory, we followed, in a short-term kinetic study, the cellular and sub-cellular localisation of circulating AGE-products throughout the nephron. AGE-peptides or AGE-BSA were injected into otherwise normal rats and detected by protein A-gold immuno-cytochemistry after 15, 30 or 45 min of circulation. Most of the AGE- BSA was found in the lumen of capillary vessels and distributed along the endothelial side of the glomerular basement membrane. Presence on mesangial matrix was also apparent. AGE-peptides were easily filtered and actively reabsorbed by the proximal convoluted tubule. At 15 min, little labelling was found in the glomerular wall. Instead, the labelling was present in the urinary space and microvilli of epithelial cells. Early endosomes displayed intense labelling as well. At 45 min, late endosomes and lysosomes added to the pattern of labelling. The distal tubule epithelial cells were devoid of labelling for any of the intervals studied. AGE-peptides but not AGE-BSA could be detected in the urine of injected rats. These observations point to participation of the endo-lysosomal apparatus of the proximal convoluted tubule to the disposal of AGE-peptides, while giving an ultrastructural support for a key role of the kidney in AGE catabolism.

Key words

Diabetes mellitus glycation colloidal gold cytochemistry glomerulosclerosis LDL clearance 

Abbreviations

AGE

Advanced glycation end products

BSA

bovine serum albumin

BHT

butylated hydroxytoluene

DEAE

diethyl aminoethyl cellulose

GBM

glomerular basement membrane

PBS

phosphate buffered saline

PMSF

phenylmethylsulphonyl fluoride

TBS

Tris buffered saline

References

  1. 1.
    Nathan D (1994) Relation between metabolic control and long-term complications of diabetes. In: Kahn CR (ed) Joslin's Diabetes Lea and Febiger, PhiladelphiaGoogle Scholar
  2. 2.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Bangstad HJ, Hanssen KF (1994) Blood glucose control and microvascular complications — what do we do now? Diabetologia 37: 1172–1177Google Scholar
  3. 3.
    The Diabetes Control and Complications Trial Data Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 977–986Google Scholar
  4. 4.
    Monnier VM, Cerami A (1981) Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491–494Google Scholar
  5. 5.
    Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 50: 385–432Google Scholar
  6. 6.
    Brownlee M (1994) Glycation and diabetic complications. Diabetes 43: 836–841Google Scholar
  7. 7.
    Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138–151Google Scholar
  8. 8.
    Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23: 1–19Google Scholar
  9. 9.
    Brownlee M, Vlassara H, Cerami A. (1987) The pathogenetic role of nonenzymatic glycosylation in diabetic complications. In: MJC Crabbe (ed) Diabetic complications: scientific and clinical aspects. Churchill Livingston, London p94Google Scholar
  10. 10.
    Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315–1321Google Scholar
  11. 11.
    Brownlee M (1990) Advanced products of non-enzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H, Porte D Jr (eds) Diabetes mellitus: theory and practice. Elsevier, New York, pp 279–291Google Scholar
  12. 12.
    Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87: 432–438Google Scholar
  13. 13.
    Bucala R, Model P, Cerami A (1984) Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci USA 81: 105–109Google Scholar
  14. 14.
    Bucala R, Vlassara H, Cerami A (1992) Advanced glycosylation end-products. In: Harding JJ Crabbe, MJC (ed) Post-translational modifications of proteins, vol 2. CRC Press Inc, Boca Raton, pp 53–179Google Scholar
  15. 15.
    Makita Z, Bucala R, Rayfield EJ et al. (1994) Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 343: 1519–1522Google Scholar
  16. 16.
    Vlassara H, Fuh H, Makita Z, Krungkrai, Cerami A, Bucala R (1992) Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89: 12043–12047Google Scholar
  17. 17.
    Makita Z, Vlassara H, Rayfield E et al. (1992) Hemoglobin- AGE: a circulating marker for advanced glycosylation. Science 258: 651–653Google Scholar
  18. 18.
    Makita Z, Radoff S, Rayfield EJ et al. (1991) Advanced glycosylation end products in patients with diabetic nephropathy. New Engl J Med 325: 836–842Google Scholar
  19. 19.
    Schmidt AM, Mora R, Cao K et al. (1994) The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269: 9882–9888Google Scholar
  20. 20.
    Schmidt AM, Vianna M, Gerlach J et al. (1992) Isolation and characterization of two binding proteins for advanced glycation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267: 14987–14997Google Scholar
  21. 21.
    Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclerosis and Thrombosis 14: 1521–1528Google Scholar
  22. 22.
    Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor specific increase in extracellular matrix production in mouse mesangial cells by advanced glycation end products is mediated via platelet derived growth factor. Proc Natl Acad Sci USA 89: 2873–2877Google Scholar
  23. 23.
    Horii Y, Skolnik E, Suthanthiran M, Vlassara H (1992) Novel T-cell receptors for advanced glycation endproducts (AGE) mediate production of IFN. Diabetes 41: 59A (Abstract)Google Scholar
  24. 24.
    Neper M, Schmidt AM, Brett J et al. (1992) Cloning and expression of RAGE: a cell surface receptor for advanced glycation end products of proteins. J Biol Chem 267: 14998–15004Google Scholar
  25. 25.
    Vlassara H, Moldawer L, Chan B (1989) Macrophage/monocyte receptor for nonenzymatically glycosylated proteins is up-regulated by cachectin/tumor necrosis factor. J Clin Invest 84: 1813–1820Google Scholar
  26. 26.
    Vlassara H, Brownlee M, Cerami A (1988) Specific macrophage receptor activity for advanced glycosylation endproducts inversely correlates with insulin levels in vivo. Diabetes 37: 456–461Google Scholar
  27. 27.
    Radoff S, Vlassara H, Cerami A (1988) Characterization of a solubilized cell surface binding protein on macrophages specific for protein modified nonenzymatically by advanced glycosylation endproducts. Arch Biochem Biophys 263: 418–423Google Scholar
  28. 28.
    Vlassara H, Brownlee M, Cerami A (1986) Novel macrophage receptor for glucose-modified protein is distinct from previously described scavenger receptors. J Exp Med 164: 1301–1309Google Scholar
  29. 29.
    Yan SD, Schmidt AM, Anderson GM et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889–9897Google Scholar
  30. 30.
    Wautier JL, Wautier MP, Schmidt AM et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91: 7742–7746Google Scholar
  31. 31.
    Bucala R, Makita Z, Vega G et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dislipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91: 9441–9445Google Scholar
  32. 32.
    Deppisch R, Nawroth P (1994) Toxicity of uraemia-does it come of AGE? Nephrol Dial Transplant 9: 1–2Google Scholar
  33. 33.
    Makita Z, Radoff S, Rayfield EJ, Yang, Z (1991) Clinical assessment and significance of advanced glycation in patients with diabetic nephropathy. New Engl J Med 325: 836–842Google Scholar
  34. 34.
    Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP (1994) Immunological quantification of advanced glycation end products in the serum of patients on hemodialysis or CAPD. Kidney Int 46: 216–222Google Scholar
  35. 35.
    Mitsuhashi T, Nakayama H, Itch T et al. (1993) Immunochemical detection of advanced glycation end products in renal cortex from streptozotocin-induced diabetic rats. Diabetes 42: 826–833Google Scholar
  36. 36.
    Kobert SM, Makita Z, Firanek CA, Vlassara H (1993) Advanced glycation end products in continuous ambulatory peritoneal dialysis patients. A J Kidney Dis 22: 588–591Google Scholar
  37. 37.
    Horiuchi S, Araki N, Morino Y (1991) Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: evidence for the presence of a common structure. J Biol Chem 266: 7329–7332Google Scholar
  38. 38.
    Gugliucci A, Bendayan M (1995) Reaction of advanced glycation products with renal tissue from normal and streptozotocin-induced diabetic rats. An ultrastructural study using colloidal gold cytochemistry. J Histochem Cytochem 43: 591–600Google Scholar
  39. 39.
    Vlassara H, Striker LJ, Teichberg S, Fuh H, Ming LY, Steffes M (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91: 11704–11708Google Scholar
  40. 40.
    Sell DR, Monnier VM (1990) End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85(2):380–384Google Scholar
  41. 41.
    Fuh H, Yang D, Striker L, Striker G, Vlassara H (1992) In vivoAGE-peptide injection induces kidney enlargement and glomerular hypertrophy in rabbits: prevention by aminoguanidine. Diabetes 41[Suppl]:9A (Abstract)Google Scholar
  42. 42.
    Njoroge FG, Sayre LM, Monnier VM (1987) Detection of D- glucose derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohyd Res 167: 211Google Scholar
  43. 43.
    Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM (1989) Aging of proteins: immunological detection of a glucose derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 264: 3758–3764Google Scholar
  44. 44.
    Njoroge FG, Monnier VM (1989) The chemistry of the Maillard reaction under physiological conditions: a review. Prog Clin Biol Res 304: 85–91Google Scholar
  45. 45.
    Steinbrecher UP (1987) Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 262: 3603–3610Google Scholar
  46. 46.
    Laemmli UK (1970) Cleavage of stuctural proteins during assembly of the head of bacteriophage T4. Nature 227: 680–685Google Scholar
  47. 47.
    Bjerrum OJ, Schafer-Nielsen C (1986) In: Dun MJ (ed) Analytical electrophoresis. Chemie, Weinheim, p 315Google Scholar
  48. 48.
    Hammes BD (1981) An introduction to polyacrylamide gel electrophoresis. In: Hammes BD, Rickwood D (eds) Gel electrophoresis of proteins: a practical approach. IRL Press Ltd, London, pp 1–19Google Scholar
  49. 49.
    Schumaker VN, Puppione D (1986) Sequential flotation ultracentrifugation. Methods Enzymol 128: 155–170Google Scholar
  50. 50.
    Forte TM, Nordhausen RW (1986) Electron microscopy of negatively stained lipoproteins. Methods Enzymol 128: 442–457Google Scholar
  51. 51.
    Nakayama H, Taneda S, Kuwajima S et al. (1989) Production and characterisation of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 162: 740–747Google Scholar
  52. 52.
    Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycation end products in vivo. J Biol Chem 267: 5133–5138Google Scholar
  53. 53.
    Harlow E, Lane D (1988) Immunization. In: Harlow E, Lane D (ed) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, New York, pp 53–137Google Scholar
  54. 54.
    Harlow E, Lane D (1988) Purification and storage of antibodies. In: Harlow E, Lane D (ed) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, New York, pp 283–318Google Scholar
  55. 55.
    Smith P, Krohn R, Hermanson G et al. (1985) Measurement of protein using bicinconinic acid. Anal Biochem 150: 76–85Google Scholar
  56. 56.
    Bendayan M (1984) Protein A-gold electron microscopic immunocytochemistry: methods, applications and limitations. J Elec Micros Tec 1: 243–270Google Scholar
  57. 57.
    Bendayan M, Gingras D, Charest P (1986) Distribution of endogenous albumin in the glomerular wall of streptozotocin-induced diabetic rats. Diabetologia 29: 868–875Google Scholar
  58. 58.
    Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H (1991) Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 174: 931–939Google Scholar
  59. 59.
    Dobrian A, Simionescu M (1995) Irreversibly glycated albumin alters the physico-chemical characteristics of low density lipoproteins of normal and diabetic subjects. Biochim Biophys Acta 1270: 26–35Google Scholar
  60. 60.
    Takahashi M, Ohishi T, Aoshima H et al. (1993) The Maillard protein cross-link pentosidine in urine from diabetic patients. Diabetologia 36: 664–667Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • A. Gugliucci
    • 1
  • M. Bendayan
    • 1
  1. 1.Department of AnatomyUniversité de MontréalMontréalCanada

Personalised recommendations